Prognostic Value of the Urokinase-Type Plasminogen Activator, and its Inhibitors and Receptor in Breast Cancer Patients

2002 ◽  
Vol 3 (2) ◽  
pp. 138-146 ◽  
Author(s):  
S. Borstnar ◽  
I. Vrhovec ◽  
B. Svetic ◽  
Tanja Cufer
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator

Urokinase-type plasminogen activator in plasma from breast cancer patients

1988 ◽  
Vol 24 (9) ◽  
pp. 1553
Author(s):  
F. Bach ◽  
J. Grøndahl-Hansen ◽  
N. Agerlin ◽  
P. Munkholm-Larsen ◽  
L.S. Nielsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator

Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers

2002 ◽  
Vol 30 (2) ◽  
pp. 207-210 ◽  
Author(s):  
M. J. Duffy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Prospective Trial ◽  
Axillary Node ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Pai 1

Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis. Multiple studies have shown that breast cancer patients whose primary cancer contains high levels of uPA have a significantly worse outcome than patients with low levels. As a prognostic marker for breast cancer the information supplied by uPA is both independent of traditionally used factors and significant in the important subgroup of axillary-node patients. Paradoxically, high levels of plasminogen activator inhibitor-1 (PAI-1), an endogenous inhibitor of uPA, also predict for aggressive disease. Recently, the prognostic impact of both uPA and PAI-1 in axillary node-negative breast cancer was confirmed using two different Level 1 Evidence studies, i.e. in both a randomized prospective trial and a pooled analysis. Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients

Prognostic value of urokinase-type plasminogen activator (UPA) and its inhibitor PAI-1 in breast cancer

1993 ◽  
Vol 29 ◽  
pp. S31
Author(s):  
M. Schmitt ◽  
F. Jänicke ◽  
C. Thomssen ◽  
L. Pache ◽  
J. Bläser ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Prognostic Value ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Pai 1

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

2004 ◽  
Vol 91 (03) ◽  
pp. 450-456 ◽  
Author(s):  
Ronald Kates ◽  
Katja Gauger ◽  
Amina Willems ◽  
Marion Kiechle ◽  
Viktor Magdolen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Low Levels ◽  
Pai 1

SummaryUrokinase-type plasminogen activator (uPA) and its inhibitor, PAI-1, play a key role in tumor invasion and metastasis. They were the first novel tumor biological factors to be validated at the highest level of evidence (LOE I) regarding their clinical utility in breast cancer. Their antigen levels are determined in tumor tissue extracts by standardized, quality-assured immunometric assays (ELISA). Since the late 1980s, numerous independent studies have demonstrated that patients with low levels of uPA and PAI-1 in their primary tumor tissue have a significantly better survival than patients with high levels of either factor. These prognostic data have recently been validated by an EORTC (European Organization for Research and Treatment of Cancer) pooled analysis comprising more than 8,000 breast cancer patients. In addition, results from a multicenter prospective randomized therapy trial in node-negative breast cancer (“Chemo N0”) showed that node-negative breast cancer patients with low levels of uPA and PAI-1 in their primary tumor have a very good prognosis, and may thus be candidates for being spared the burden of adjuvant chemotherapy. In contrast, node-negative patients with high uPA/PAI-1 are at substantially increased risk of disease recurrence, comparable to that of patients with three or more tumor cell positive axillary lymph nodes. The “Chemo N0” trial as well as retrospective data also indicate that these high-risk patients benefit from adjuvant chemotherapy. In conclusion, over a period of about 15 years sufficient evidence has been put forward to demonstrate that determination of uPA and PAI-1 in primary breast cancer patients supports risk-adapted individualized therapy decisions, particularily in patients with node-negative disease.

Sign in / Sign up

Export Citation Format

Share Document